Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.

Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.

Blood Cells Mol Dis. 2011 Jan 15;46(1):119-23. doi: 10.1016/j.bcmd.2010.07.008. Epub 2010 Aug 19.

PMID:
20727796
2.

Velaglucerase alfa for the management of type 1 Gaucher disease.

Morris JL.

Clin Ther. 2012 Feb;34(2):259-71. doi: 10.1016/j.clinthera.2011.12.017. Epub 2012 Jan 20. Review.

PMID:
22264444
3.

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.

Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D.

Blood. 2010 Jun 10;115(23):4651-6. doi: 10.1182/blood-2010-02-268649. Epub 2010 Mar 18.

4.

Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.

Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A.

Blood Cells Mol Dis. 2011 Jun 15;47(1):56-61. doi: 10.1016/j.bcmd.2011.04.005. Epub 2011 May 4.

PMID:
21536468
5.

Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.

Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.

Am J Hematol. 2015 Jul;90(7):592-7. doi: 10.1002/ajh.24007.

6.
7.

Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.

Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.

Am J Hematol. 2013 Mar;88(3):166-71. doi: 10.1002/ajh.23381. Epub 2013 Feb 6.

8.

Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.

Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):56-60. doi: 10.1016/j.bcmd.2014.02.006. Epub 2014 Feb 25.

PMID:
24581483
9.

Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.

Laudemann K, Moos L, Mengel E, Lollert A, Hoffmann C, Brixius-Huth M, Wagner D, Düber C, Staatz G.

Blood Cells Mol Dis. 2016 Mar;57:35-41. doi: 10.1016/j.bcmd.2015.11.003. Epub 2015 Nov 27.

PMID:
26852653
10.

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.

Blood Cells Mol Dis. 2000 Aug;26(4):285-90.

PMID:
11042029
11.

Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.

Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.

Mol Genet Metab. 2016 Feb;117(2):164-71. doi: 10.1016/j.ymgme.2015.05.012. Epub 2015 Jun 1.

12.

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.

Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D.

Genet Med. 2014 May;16(5):359-66. doi: 10.1038/gim.2013.154. Epub 2013 Nov 21.

13.

Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.

Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.

Am J Hematol. 2013 Mar;88(3):179-84. doi: 10.1002/ajh.23382. Epub 2013 Feb 9. Erratum in: Am J Hematol. 2013 Jul;88(7):632.

14.

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.

Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.

J Immunol Methods. 2011 Oct 28;373(1-2):45-53. doi: 10.1016/j.jim.2011.07.020. Epub 2011 Aug 6.

15.

Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.

Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA.

Am J Hematol. 2013 Mar;88(3):172-8. doi: 10.1002/ajh.23383. Epub 2013 Jan 22.

16.

Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.

Serratrice C, Bengherbia M, Alessandrini M, Grosbois B, Camou F, Pers YM, Bismuth M, Marie I, Belmatoug N, Berger M; Comité d'Evaluation et de Traitement de la maladie de Gaucher.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):94-6. doi: 10.1016/j.bcmd.2013.12.004. Epub 2014 Jan 7. No abstract available.

PMID:
24411065
17.

Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.

Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM.

Expert Opin Pharmacother. 2009 Nov;10(16):2641-52. doi: 10.1517/14656560903270520. Review.

PMID:
19743939
18.

Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.

Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.

Blood Cells Mol Dis. 2012 Jan 15;48(1):45-50. doi: 10.1016/j.bcmd.2011.09.009. Epub 2011 Nov 1.

PMID:
22047948
19.

Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.

Mitrovic M, Sumarac Z, Antic D, Bogdanovic A, Elezovic I, Vukosavljevic D, Ignjatovic S, Majkic-Singh N, Suvajdzic N.

Blood Cells Mol Dis. 2012 Jun 15;49(1):58-9. doi: 10.1016/j.bcmd.2012.03.003. Epub 2012 Mar 27. No abstract available.

PMID:
22459893
20.

Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.

Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G.

Am J Clin Pathol. 2013 Jul;140(1):91-6. doi: 10.1309/AJCPFVSAEGO67NGT.

PMID:
23765538

Supplemental Content

Support Center